image

PRT1419

Prelude is developing PRT1419, which is designed to be an orally available, potent, and selective inhibitor of MCL1.

Prelude is developing PRT1419, which is designed to be an orally available, potent, and selective inhibitor of MCL1. An oral formulation of PRT1419 is being evaluated in a Phase 1 trial in high-risk myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin’s lymphoma, and multiple myeloma. An intravenous formulation will be evaluated in a Phase 1 trial in patients with solid tumors.

MCL1 Graphic 2